WO2014130778A1 - A flow-through filter to remove aluminum from medical solutions - Google Patents
A flow-through filter to remove aluminum from medical solutions Download PDFInfo
- Publication number
- WO2014130778A1 WO2014130778A1 PCT/US2014/017608 US2014017608W WO2014130778A1 WO 2014130778 A1 WO2014130778 A1 WO 2014130778A1 US 2014017608 W US2014017608 W US 2014017608W WO 2014130778 A1 WO2014130778 A1 WO 2014130778A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flow
- filter assembly
- container
- filter
- connector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/28—Treatment of water, waste water, or sewage by sorption
- C02F1/285—Treatment of water, waste water, or sewage by sorption using synthetic organic sorbents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/265—Synthetic macromolecular compounds modified or post-treated polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
- B01J20/3251—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulphur
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J45/00—Ion-exchange in which a complex or a chelate is formed; Use of material as complex or chelate forming ion-exchangers; Treatment of material for improving the complex or chelate forming ion-exchange properties
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/44—Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
- C02F1/444—Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis by ultrafiltration or microfiltration
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/68—Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
- C02F1/683—Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water by addition of complex-forming compounds
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2101/00—Nature of the contaminant
- C02F2101/10—Inorganic compounds
- C02F2101/20—Heavy metals or heavy metal compounds
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2103/00—Nature of the water, waste water, sewage or sludge to be treated
- C02F2103/02—Non-contaminated water, e.g. for industrial water supply
- C02F2103/026—Treating water for medical or cosmetic purposes
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2201/00—Apparatus for treatment of water, waste water or sewage
- C02F2201/002—Construction details of the apparatus
- C02F2201/006—Cartridges
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F2209/00—Controlling or monitoring parameters in water treatment
- C02F2209/40—Liquid flow rate
Definitions
- This document relates generally to filter assemblies for removing metal ions from a solution and, more particularly, to a filter assembly capable of removing trivalent ions, such as aluminum, and tetravalent metal ions, from medical solutions.
- Aluminum (Al) is a common contaminant in many medical solutions. This is in part the result of the widespread distribution of aluminum in the environment. In addition, some medical solutions contain compounds that react strongly with aluminum and extract this metal from the surroundings, e.g. from the walls of glass containers. This strong binding increases the Al contamination and makes it much more difficult to remove the aluminum from these solutions.
- SVP small volume parenteral
- PN preparation most of the final Al content originates from the calcium gluconate SVP solution. It is noteworthy that the Al content of calcium gluconate can vary widely, depending on the commercial provider. Reported Al concentrations range from 1920 to 19,400 micrograms/L. At a typical concentration of 4,000 micrograms/L, it is estimated that calcium gluconate contributes about 80% of the aluminum in the final PN solution (Mouser et al., Am. J. Health-Syst. Pharm., 1998, 55: 1071).
- Other patient populations at risk include, but are not limited to, children with malabsorption syndrome, dialysis patients, elderly patients (due to a weakened GI protective barrier and/or normal renal function deterioration) and burn patients (due to Al-contaminated albumin to maintain oncotic pressure).
- critically ill infants and children require parenteral calcium replacement because of hypocalcemia, especially after cardiac surgery. More specifically, the amount of calcium required, provided as calcium gluconate, would lead to exposure to much greater than 5 micrograms of aluminum per kg per day. Removal of aluminum from these parenteral infusions would minimize potential aluminum-induced toxicities.
- a single-use filter to remove aluminum from a solution as it passes through the filter.
- the body of the filter is filled with a specialized chelator, such as trihydroxamate chelating resin, described in our previous US Patents 7,932,326 and 8,066,883 and US Patent Application Serial No. 13/278,498 the full disclosures of which are incorporated herein by reference.
- the other components of the filter are designed to produce a controlled fluid flow rate, using a partially evacuated vial and a flow restriction/flow controller tube that has an internal diameter and length, that when paired with the extent of vacuum in the partially evacuated vial, achieves a desired flow rate.
- the filter is designed to connect to the evacuated vial and the vial of the source SVP solution.
- Chelating resins are not new.
- Chelex 100 ® is a polystyrene resin which has iminodiacetic acid functional groups covalently linked to the resin. It is relatively nonselective, and thus is widely used to bind a large number of metal ions. However, we have determined that this type of generic chelating resin is not effective for removing aluminum from solutions such as calcium gluconate.
- a flow through filter assembly for removing trivalent and tetravalent metal ions from a solution.
- the flow through assembly includes a housing containing a hydroxamate chelating resin.
- the housing has an inlet and an outlet.
- a first vial connector is provided in fluid communication with the inlet.
- a second vial connector is provided in fluid communication with the outlet.
- the filter assembly includes a flow controller for limiting flow through the housing to a predetermined rate. In one useful embodiment that predetermined rate is less than 2.0 ml/min. In another useful embodiment the predetermined rate is less than 1.0 ml/min. In yet another useful embodiment that predetermined rate is about 1.0 ml/min.
- the first container connector is a vented spike and a first set of connector clips.
- the second container connector is a non- vented spike and a second set of connector clips.
- the second vial has a negative interior pressure before the non-vented spike is inserted into the second vial.
- a system for removing a trivalent or tetravalent metal ion from a solution.
- the system comprises a first vial including a solution from which the trivalent or tetravalent metal ion is to be removed and a second vial for receiving a treated solution.
- the second vial has a negative interior pressure.
- the system includes a filter assembly for capturing the trivalent or tetravalent metal ion. The filter assembly is connected between the first and second vials.
- the filter assembly includes a first connector for the first vial and a second connector for the second vial.
- the first connector is a vented spike and a first clamp.
- the second connector is a non- vented spike and a second clamp.
- a flow-through filter assembly for removing metal ions from a medical solution, including aluminum ions comprised of a housing including a medical solution inlet, an aluminum metal ion capturing agent having an
- the treated medical solution outlet is positioned relative to the medical solution inlet to allow flow of medical solution through the filter assembly without a mechanical pump.
- the assembly includes a flow controller for maintaining a rate of flow of medical solution through the filter assembly that allows capture of aluminum metal ions by the capturing agent.
- Figure 1 is an exploded perspective view of the flow-through filter assembly.
- Figure 2 is a perspective view of the system for removing a trivalent or tetravalent metal ion from a solution.
- Figure 3 is a detailed cross-sectional view illustrating the filter assembly.
- Figure 4 is a graph of flow rate versus restrictor tube length for a flow restrictor tube of 0.005" (0.127 mm) diameter at a draw pressure of 88,046.11 pascal (26 inHg)
- FIG. 1 generally illustrating the flow-through filter assembly 10 for removing trivalent and tetravalent metal ions from a solution.
- the flow-through assembly 10 includes a housing 12 containing a chelating agent or resin having an Al -binding constant of at least approximately 10 20 .
- chelating agent is a trihydroxamate chelating resin.
- chelating agents/resins may be used including, but not limited to, desferoxamine chelating resin, tetrahydroxamate chelating resin, hydroxypyridinone chelating resin, aminocarboxylate chelating resin, catechol chelating resin, poly-carboxylate chelating resin and mixtures thereof.
- the flow-through filter assembly 10 includes a first container connector 14 at a first end and a second container connector 16 at a second end.
- the first container connector 14 is comprised of a vented spike 15 (note vent 18) and a first set of connector clips or clamp 38.
- the second container connector 16 comprises a non- vented spike 17 and a second set of connector clips or clamp 40.
- the housing 12 contains the upper resin frit 24.
- the upper membrane housing contains the upper resin frit 24.
- the resin 20 holds the lower resin frit 26.
- the resin 25 is held between frits 24 and 26 in the housing 12 during use of the filter assembly 10 (see also Figure 3).
- the filter assembly 10 also includes a lower membrane housing 28 including a grating 30 that supports a 0.2 or 0.45 micron filter membrane 32. That membrane 32 functions to make certain that no particulates from the chelating agent or resin in the housing 12 are carried into the treated solution that is collected in the second container 104 ( Figure 2). Such a filter membrane 32 may be built-in as an integral component of the filter assembly 10. Alternatively, a 0.2 or 0.45 micron filter cartridge may be inserted between the housing 12 and the lower, non- vented spike 17.
- a flow controller 34 is provided within the control tube aperature 36 of the non-vented spike 17. This flow controller 34 functions to limit the flow of solution through the filter assembly 10 to a rate of between 0.1 and 10 ml/min. In another embodiment the flow controller 34 limits the rate of flow to less than 2.0 ml/min. In another embodiment the flow controller 34 limits the rate of flow to less than 1.0 ml/min. In yet another, the flow controller 34 limits the rate of flow to about 1.0 ml/min. In the illustrated embodiment, the flow controller 34 is a flow restrictor tube with an internal flow passage 35.
- the flow controller 34 does not have to be a tube, it can be molded directly into the spike 17, or a hole could be drilled in the spike to create a tube (passage) for fluid flow.
- the selected flow rate insures that there is sufficient time for trivalent and tetravalent metal ions in the solution to be captured by the chelating agent in the housing 12 as the solution flows through the housing 12.
- the first set of clips 38 is engineered to snuggly clip onto the caps of a commercial container of SVP solution while the second set of clips 40 is engineered to snuggly clip onto an appropriately sized evacuated container so that the working system 100 (see Figure 2) can be assembled conveniently and quickly and with no other clamping devices.
- the system 100 incudes: (a) a first vial or container 102 including a solution from which the trivalent or tetravalent ion is to be removed; (b) a second vial or container 104 for receiving a treated solution; and (c) the filter assembly 10 for capturing the trivalent or tetravalent metal ion. More specifically, as shown in Figure 1 the clips 38 at the first end of the filter assembly 10 engage a cap 106 ( Figure 2) of the first container 102 effectively holding the vented spike 15, that is inserted into the vial through a puncturable seal in the cap, in fluid communication with the solution contained in the container.
- the second set of clips 40 at the second end of the filter assembly 10 engage the cap 108 of the second container 104 effectively holding the non- vented spike 17, that is inserted into the vial through a puncturable seal in the cap, in fluid communication with the interior chamber of that container.
- the vent 18 to ambient atmosphere provided on the vented spike 15 works in conjunction with the negative pressure in the chamber of the second container 104 to produce a steady flow of solution from the first container 102 through the filter assembly 10 including the chelating agent or resin held in the housing 12 and the 0.2 or 0.45 micron membrane 32 to the chamber of the container 104.
- the chelating agent or resin in the housing 12 is specifically designed for high aluminum binding affinity enabling efficient extraction of aluminum even from solutions that contain high concentrations of competing aluminum complexing agents such as gluconate or phosphate.
- the trihydroxamate resin has an aluminum-binding constant of approximately 10 20. This binding is strong enough to compete with the aluminum-binding ligands present in contaminated SVP solutions. However, the rate at which the aluminum binds to the resin is a critical factor. This rate can be slow, either because of the slow chemical exchange of aluminum between the solution and the immobilized chelating agent or because of the time required for the solution to pass through the porous structure of the resin beads.
- a key element in the design of the filter assembly is the ability to regulate the rate of flow of liquid through the filter assembly 10 to ensure sufficient contact time with the resin to produce effective aluminum removal.
- the filter assembly 10 includes the flow controller 34 built in the control tube aperature 36 of the lower spike (see Figure 3).
- the inner diameter and length of the flow restriction/flow controller tube 34 is selected to produce the appropriate flow rate for efficient aluminum removal from the targeted medical solution, in concert with the level of reduced pressure in the second container, and other components of the filter 10. More specifically, a larger inner diameter flow restriction/flow controller tube 34 provides a faster flow rate. In contrast, a smaller inner diameter flow restriction/flow controller tube 34 provides a slower flow rate.
- the flow restrictor tube 34 of the illustrated embodiment includes the flow passage 35 which has a predetermined length L of between about 5 mm and about 20 mm and a predetermined diameter of between about 0.0508 mm and about 0.1778 mm.
- the second container 104 has a negative interior pressure P of between about 84,659.72 pascal and about 94,818.88 pascal. The difference in the ambient pressure provided in the first container 102 by the vent 18 on the spike 15 and the negative pressure in the second container 104 functions to pull the solution through the filter assembly 10, including the flow passage 35.
- the flow passage length L, the flow passage diameter D and the second container interior pressure P function together to provide the desired rate of flow of solution through the filter assembly 10.
- the filter assembly 10 is engineered to provide the proper flow rate for removing the desired trivalent and/or tetravalent metal ions from the solution being treated.
- the operator does not need to adjust any pumps or monitor any equipment to provide the required flow rate.
- proper filtering of trivalent and tetravalent metal ions from the solution is ensured with minimal potential for any error.
- the trihydroxamate chelating resin was initially tested in stirred, batch extractions to establish its ability to remove Al from calcium gluconate.
- a 1 g sample of resin was added to 100 ml of commercial calcium gluconate solution that was gently agitated by an overhead stirrer. In this configuration, the resin removed 80% of the Al.
- the binding constant of the ligand immobilized on the resin was calculated to be 10 20'4 .
- the flow rate of calcium gluconate through the filter is about 1 ml/min.
- Flow rate will be a function of the inner diameter of the flow restriction/flow controller tube 34, the length of the flow restriction/flow controller tube 34, the level of vacuum in the second container 104, the viscosity of the fluid flowing through the filter assembly 10, and other properties of the filter.
- the amount of resin loaded into the body of the cartridge was also varied. In four replicate experiments, 1 g of resin removed 91 to 95% of the aluminum from a commercial calcium gluconate solution that had an initial Al concentration of -4,000 micrograms/L. Further tests showed that 800 mg of resin removed 79% of the Al, and 600 mg of resin removed only 64% of the Al.
- the column/cartridge 12 of the present filter assembly 10 has been engineered to hold 1 g of resin.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hydrology & Water Resources (AREA)
- Engineering & Computer Science (AREA)
- Environmental & Geological Engineering (AREA)
- Water Supply & Treatment (AREA)
- External Artificial Organs (AREA)
Abstract
A flow through filter assembly includes a trivalent and tetravalent metal ion capturing agent and a flow controller providing a predetermined flow rate which allows capture of the trivalent and tetravalent metal ions by the capturing agent. Preferred capturing agents include trihydroxamate resins and the preferred flow controller includes a flow restrictor tube.
Description
A FLOW-THROUGH FILTER TO REMOVE ALUMINUM FROM MEDICAL
SOLUTIONS
TECHNICAL FIELD
[0001] This document relates generally to filter assemblies for removing metal ions from a solution and, more particularly, to a filter assembly capable of removing trivalent ions, such as aluminum, and tetravalent metal ions, from medical solutions.
BACKGROUND
[0002] Aluminum (Al) is a common contaminant in many medical solutions. This is in part the result of the widespread distribution of aluminum in the environment. In addition, some medical solutions contain compounds that react strongly with aluminum and extract this metal from the surroundings, e.g. from the walls of glass containers. This strong binding increases the Al contamination and makes it much more difficult to remove the aluminum from these solutions.
[0003] Healthy adults are generally protected against oral aluminum toxicity by the fact that less than 1% of an oral dose of aluminum is absorbed from the intestine. In addition, the urinary excretion of aluminum is relatively effective for persons with normal kidney function.
[0004] There is a special concern regarding aluminum exposure to premature neonates. These infants routinely require several or more days of parenteral nutrition (PN) until they can tolerate oral feeding. The PN bypasses the normal protection associated with low intestinal absorption of Al. In addition, these infants often have underdeveloped kidney function (the primary route of Al elimination), which impedes the excretion of the aluminum contained in the PN solution.
[0005] It is well known that some of the small volume parenteral (SVP) solutions used to prepare the final PN solutions are heavily contaminated with aluminum. Poole, coworkers and others have extensively documented the Al content of SVP solutions, as shown
in Table 1.
Table 1. Aluminum content of the most contaminated SVP solutions
Solution Aluminum concentration (micro grams/L)
Calcium gluconate 3234 and 1920 to 34951, 4900 (new) and 6145 (old glass ampoules)2, 9205 and 19,4003
Potassium phosphate 8280 and 3650 to 16,82ο1
Sodium Phosphate 622 and 17 to 32811
Multi-trace elements 414 and 101 to 7391, 1049 and 20653
Potassium Lactate 15004
Potassium Acetate 42 and 11 to 11201
Sodium acetate 83 and 54 to 1381
^rom Poole et al., Pediatr. Gastroenterol. Nutr. 2010, 50: 208; Poole et al., J. Pediatr.
Pharmacol. Ther. 2011,16: 92.
2From Beaney and Smeaton, Congress of the European Association of Hospital Pharmacists, 2010.
3From de Oliveira et al., JPEN J Parenter Enteral Nutr 2010, 34: 322-328.
4From Advenier et al., J. Pediatr. Gastroenterol. Nutr. 2003, 36: 448.
[0006] Because of the relative volumes of each of these solutions included in a typical
PN preparation, most of the final Al content originates from the calcium gluconate SVP solution. It is noteworthy that the Al content of calcium gluconate can vary widely, depending on the commercial provider. Reported Al concentrations range from 1920 to 19,400 micrograms/L. At a typical concentration of 4,000 micrograms/L, it is estimated that calcium gluconate contributes about 80% of the aluminum in the final PN solution (Mouser et al., Am. J. Health-Syst. Pharm., 1998, 55: 1071).
[0007] The FDA has formally recognized the problem of potential Al toxicity to premature infants. It has established a safe level of Al exposure as 4 to 5 micrograms/kg/d. However, it is widely recognized that currently the U.S. pharmaceutical industry cannot supply SVP component solutions that allow pediatric pharmacists to prepare PN solutions that meet this exposure limit.
[0008] Other patient populations at risk include, but are not limited to, children with
malabsorption syndrome, dialysis patients, elderly patients (due to a weakened GI protective barrier and/or normal renal function deterioration) and burn patients (due to Al-contaminated albumin to maintain oncotic pressure). In addition, critically ill infants and children require parenteral calcium replacement because of hypocalcemia, especially after cardiac surgery. More specifically, the amount of calcium required, provided as calcium gluconate, would lead to exposure to much greater than 5 micrograms of aluminum per kg per day. Removal of aluminum from these parenteral infusions would minimize potential aluminum-induced toxicities.
[0009] Disclosed herein is a single-use filter to remove aluminum from a solution as it passes through the filter. The body of the filter is filled with a specialized chelator, such as trihydroxamate chelating resin, described in our previous US Patents 7,932,326 and 8,066,883 and US Patent Application Serial No. 13/278,498 the full disclosures of which are incorporated herein by reference. The other components of the filter are designed to produce a controlled fluid flow rate, using a partially evacuated vial and a flow restriction/flow controller tube that has an internal diameter and length, that when paired with the extent of vacuum in the partially evacuated vial, achieves a desired flow rate. The filter is designed to connect to the evacuated vial and the vial of the source SVP solution.
[0010] Chelating resins are not new. Chelex 100® is a polystyrene resin which has iminodiacetic acid functional groups covalently linked to the resin. It is relatively nonselective, and thus is widely used to bind a large number of metal ions. However, we have determined that this type of generic chelating resin is not effective for removing aluminum from solutions such as calcium gluconate.
[0011] The concept of a flow-through filter for removing contaminants from aqueous solutions is also widely used. There are many examples of point-of-use filters for home faucets to remove both metal ions and organic contaminants. These typically remove metal ions by simple cation exchange. Thus they are not designed to compete against strong Al- binding ligands in the solution. More specialized chelating resins have been used in filters in research labs, but they have not been applied to the removal of aluminum from SVP solutions.
[0012] Flow-through filters have been used in medical settings. The chelating agent desferoxamine has been physically imbedded into a hollow-fiber filter for the extracorporeal removal of iron and aluminum from blood during hemodialysis. Desferoxamine has also been covalently bound to silica for the extracorporeal removal of metal ions from blood. Neither of these filters has been suggested for use in a pharmaceutical setting for removing aluminum from SVP solutions.
SUMMARY
[0013] In accordance with the purposes noted above, a flow through filter assembly is provided for removing trivalent and tetravalent metal ions from a solution. In one embodiment, the flow through assembly includes a housing containing a hydroxamate chelating resin. The housing has an inlet and an outlet. A first vial connector is provided in fluid communication with the inlet. A second vial connector is provided in fluid communication with the outlet. Further the filter assembly includes a flow controller for limiting flow through the housing to a predetermined rate. In one useful embodiment that predetermined rate is less than 2.0 ml/min. In another useful embodiment the predetermined rate is less than 1.0 ml/min. In yet another useful embodiment that predetermined rate is about 1.0 ml/min.
[0014] In one useful embodiment the first container connector is a vented spike and a first set of connector clips. In another useful embodiment the second container connector is a non- vented spike and a second set of connector clips. The second vial has a negative interior pressure before the non-vented spike is inserted into the second vial.
[0015] In accordance with an additional aspect a system is provided for removing a trivalent or tetravalent metal ion from a solution. The system comprises a first vial including a solution from which the trivalent or tetravalent metal ion is to be removed and a second vial for receiving a treated solution. The second vial has a negative interior pressure. Further the system includes a filter assembly for capturing the trivalent or tetravalent metal ion. The filter assembly is connected between the first and second vials.
[0016] The filter assembly includes a first connector for the first vial and a second connector for the second vial. The first connector is a vented spike and a first clamp. The
second connector is a non- vented spike and a second clamp.
[0017] In accordance with yet another aspect, a flow-through filter assembly for removing metal ions from a medical solution, including aluminum ions, comprised of a housing including a medical solution inlet, an aluminum metal ion capturing agent having an
Al-binding constant of at least approximately 10 20 held in the vessel and a treated medical solution outlet. The treated medical solution outlet is positioned relative to the medical solution inlet to allow flow of medical solution through the filter assembly without a mechanical pump. Further, the assembly includes a flow controller for maintaining a rate of flow of medical solution through the filter assembly that allows capture of aluminum metal ions by the capturing agent.
[0018] In the following description there are shown and described a number of different embodiments of a flow-through filter assembly and an associated system. It should be realized that the flow-through filter assembly and system are capable of still other different embodiments and their several details are capable of modification and various obvious aspects. Accordingly, the drawings and descriptions will be regarded as illustrative in nature and not as restrictive.
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] The accompanying drawings incorporated herein and forming a part of the specification, illustrate several aspects of the filter assembly and system and together with the description serve to explain certain principles thereof. In the drawings:
[0020] Figure 1 is an exploded perspective view of the flow-through filter assembly.
[0021] Figure 2 is a perspective view of the system for removing a trivalent or tetravalent metal ion from a solution.
[0022] Figure 3 is a detailed cross-sectional view illustrating the filter assembly.
[0023] Figure 4 is a graph of flow rate versus restrictor tube length for a flow restrictor tube of 0.005" (0.127 mm) diameter at a draw pressure of 88,046.11 pascal (26 inHg)
[0024] Reference will now be made in detail to the present preferred embodiments of the flow-through filter assembly and system illustrated in the accompanying drawings.
DETAILED DESCRIPTION
[0025] Reference is now made to Figure 1 generally illustrating the flow-through filter assembly 10 for removing trivalent and tetravalent metal ions from a solution. The flow-through assembly 10 includes a housing 12 containing a chelating agent or resin having an Al -binding constant of at least approximately 1020. In one useful embodiment that chelating agent is a trihydroxamate chelating resin. It should be appreciated, however, that other chelating agents/resins may be used including, but not limited to, desferoxamine chelating resin, tetrahydroxamate chelating resin, hydroxypyridinone chelating resin, aminocarboxylate chelating resin, catechol chelating resin, poly-carboxylate chelating resin and mixtures thereof.
[0026] As further illustrated in Figure 1, the flow-through filter assembly 10 includes a first container connector 14 at a first end and a second container connector 16 at a second end. In one possible embodiment the first container connector 14 is comprised of a vented spike 15 (note vent 18) and a first set of connector clips or clamp 38. In one possible embodiment the second container connector 16 comprises a non- vented spike 17 and a second set of connector clips or clamp 40.
[0027] The housing 12 contains the upper resin frit 24. The upper membrane housing
20 holds the lower resin frit 26. The resin 25 is held between frits 24 and 26 in the housing 12 during use of the filter assembly 10 (see also Figure 3).
[0028] The filter assembly 10 also includes a lower membrane housing 28 including a grating 30 that supports a 0.2 or 0.45 micron filter membrane 32. That membrane 32 functions to make certain that no particulates from the chelating agent or resin in the housing 12 are carried into the treated solution that is collected in the second container 104 (Figure 2). Such a filter membrane 32 may be built-in as an integral component of the filter assembly 10. Alternatively, a 0.2 or 0.45 micron filter cartridge may be inserted between the housing 12 and the lower, non- vented spike 17.
[0029] As further illustrated in Figures 1 and 3, a flow controller 34 is provided
within the control tube aperature 36 of the non-vented spike 17. This flow controller 34 functions to limit the flow of solution through the filter assembly 10 to a rate of between 0.1 and 10 ml/min. In another embodiment the flow controller 34 limits the rate of flow to less than 2.0 ml/min. In another embodiment the flow controller 34 limits the rate of flow to less than 1.0 ml/min. In yet another, the flow controller 34 limits the rate of flow to about 1.0 ml/min. In the illustrated embodiment, the flow controller 34 is a flow restrictor tube with an internal flow passage 35. It should be appreciated that the flow controller 34 does not have to be a tube, it can be molded directly into the spike 17, or a hole could be drilled in the spike to create a tube (passage) for fluid flow. The selected flow rate insures that there is sufficient time for trivalent and tetravalent metal ions in the solution to be captured by the chelating agent in the housing 12 as the solution flows through the housing 12.
[0030] As previously noted, it should be appreciated that the first container connector
14 includes the first set of clips 38 and the second container connector 16 includes the second set of clips 40. More specifically, the first set of clips 38 is engineered to snuggly clip onto the caps of a commercial container of SVP solution while the second set of clips 40 is engineered to snuggly clip onto an appropriately sized evacuated container so that the working system 100 (see Figure 2) can be assembled conveniently and quickly and with no other clamping devices.
[0031] More specifically, with reference to Figure 2, the system 100 incudes: (a) a first vial or container 102 including a solution from which the trivalent or tetravalent ion is to be removed; (b) a second vial or container 104 for receiving a treated solution; and (c) the filter assembly 10 for capturing the trivalent or tetravalent metal ion. More specifically, as shown in Figure 1 the clips 38 at the first end of the filter assembly 10 engage a cap 106 (Figure 2) of the first container 102 effectively holding the vented spike 15, that is inserted into the vial through a puncturable seal in the cap, in fluid communication with the solution contained in the container. Similarly, the second set of clips 40 at the second end of the filter assembly 10 engage the cap 108 of the second container 104 effectively holding the non- vented spike 17, that is inserted into the vial through a puncturable seal in the cap, in fluid communication with the interior chamber of that container. The vent 18 to ambient atmosphere provided on the vented spike 15 works in conjunction with the negative pressure in the chamber of the second container 104 to produce a steady flow of solution from the first
container 102 through the filter assembly 10 including the chelating agent or resin held in the housing 12 and the 0.2 or 0.45 micron membrane 32 to the chamber of the container 104. It should be appreciated that the chelating agent or resin in the housing 12 is specifically designed for high aluminum binding affinity enabling efficient extraction of aluminum even from solutions that contain high concentrations of competing aluminum complexing agents such as gluconate or phosphate.
[0032] More specifically, in one possible embodiment the trihydroxamate resin has an aluminum-binding constant of approximately 10 20. This binding is strong enough to compete with the aluminum-binding ligands present in contaminated SVP solutions. However, the rate at which the aluminum binds to the resin is a critical factor. This rate can be slow, either because of the slow chemical exchange of aluminum between the solution and the immobilized chelating agent or because of the time required for the solution to pass through the porous structure of the resin beads. Thus, a key element in the design of the filter assembly is the ability to regulate the rate of flow of liquid through the filter assembly 10 to ensure sufficient contact time with the resin to produce effective aluminum removal. Toward this end, the filter assembly 10 includes the flow controller 34 built in the control tube aperature 36 of the lower spike (see Figure 3). The inner diameter and length of the flow restriction/flow controller tube 34 is selected to produce the appropriate flow rate for efficient aluminum removal from the targeted medical solution, in concert with the level of reduced pressure in the second container, and other components of the filter 10. More specifically, a larger inner diameter flow restriction/flow controller tube 34 provides a faster flow rate. In contrast, a smaller inner diameter flow restriction/flow controller tube 34 provides a slower flow rate.
[0033] Still more specifically, the flow restrictor tube 34 of the illustrated embodiment includes the flow passage 35 which has a predetermined length L of between about 5 mm and about 20 mm and a predetermined diameter of between about 0.0508 mm and about 0.1778 mm. Further the second container 104 has a negative interior pressure P of between about 84,659.72 pascal and about 94,818.88 pascal. The difference in the ambient pressure provided in the first container 102 by the vent 18 on the spike 15 and the negative pressure in the second container 104 functions to pull the solution through the filter assembly 10, including the flow passage 35. Thus, it should be appreciated that the flow passage
length L, the flow passage diameter D and the second container interior pressure P function together to provide the desired rate of flow of solution through the filter assembly 10.
[0034] Accordingly, the filter assembly 10 is engineered to provide the proper flow rate for removing the desired trivalent and/or tetravalent metal ions from the solution being treated. The operator does not need to adjust any pumps or monitor any equipment to provide the required flow rate. Thus, proper filtering of trivalent and tetravalent metal ions from the solution is ensured with minimal potential for any error.
[0035] The following examples are presented to further illustrate the flow-through filter 10 and system 100.
Example. Removal of Al from commercial calcium gluconate solutions
[0036] We have prepared a filter assembly 10 specifically engineered for the removal of Al from calcium gluconate. The upper connector 14 is engineered to fit the neck of standard 10, 50 and 100 ml vials 102 of calcium gluconate.
[0037] The trihydroxamate chelating resin was initially tested in stirred, batch extractions to establish its ability to remove Al from calcium gluconate. A 1 g sample of resin was added to 100 ml of commercial calcium gluconate solution that was gently agitated by an overhead stirrer. In this configuration, the resin removed 80% of the Al. Based on the Al-binding constants of gluconate, the binding constant of the ligand immobilized on the resin was calculated to be 1020'4.
[0038] Approximately lg of ligand was loaded into a housing 12, and a calcium gluconate solution was pulled through the filter by an evacuated collection vial 104. The fraction of Al removed at various flow rates was measured. Aluminum removal is inversely related to flow rate. The flow can be changed by changing the inner diameter and length of the flow restriction/flow controller tube and the partial vacuum. Different applications may require a different flow rate. Thus the inner diameter of the flow restriction/flow controller tube 34 in the present embodiment has been adjusted to produce a flow of calcium gluconate of ~1 ml/min. For example, where the lower spike 17 has a flow restriction/flow controller
tube 34 with an inner flow diameter of about 0.004 inches and a length of about 9/16 inches, the flow rate of calcium gluconate through the filter is about 1 ml/min. Flow rate will be a function of the inner diameter of the flow restriction/flow controller tube 34, the length of the flow restriction/flow controller tube 34, the level of vacuum in the second container 104, the viscosity of the fluid flowing through the filter assembly 10, and other properties of the filter. For example, for eight experiments, where the flow restriction/flow controller tube inner diameter was 0.004", its length 9 mm and the level of vacuum in the second container 104 was negative 27.1 ± 0.1 inches of mercury in relation to atmospheric pressure, the flow rate of calcium gluconate averaged 0.93 ml/min. For six experiments, where the flow restriction/flow controller tube inner diameter was 0.004", its length 10 mm and the level of vacuum in the second container 104 was negative 27 inches of mercury in relation to atmospheric pressure, the average flow rate of calcium gluconate was 0.92 g/min. For twelve experiments, where the flow restriction/flow controller tube inner diameter was 0.004", its length 12 mm and the level of vacuum in the second container 104 was negative 27.5 inches of mercury, the average flow rate of calcium gluconate was 1.25 g/min. When nine experiments were conducted for which the inner diameter of the flow restriction/flow controller tube inner diameter was 0.005", its length was varied, and the level of vacuum in the second container 104 was 26 inches of mercury, calcium gluconate flow rate inversely related to the length of the flow restriction/flow controller tube (Figure 4). These are examples of the method to control the flow rate using two dimensions of the flow restriction/flow controller tube 34 (internal diameter and length) with the level of vacuum in the second container 104. Other dimensions of these three variables can be used to achieve the same flow rate. Other properties of the filter, such as the membranes, also influence the flow rate.
[0039] The amount of resin loaded into the body of the cartridge was also varied. In four replicate experiments, 1 g of resin removed 91 to 95% of the aluminum from a commercial calcium gluconate solution that had an initial Al concentration of -4,000 micrograms/L. Further tests showed that 800 mg of resin removed 79% of the Al, and 600 mg of resin removed only 64% of the Al. The column/cartridge 12 of the present filter assembly 10 has been engineered to hold 1 g of resin.
[0040] Since the Al concentration in commercial calcium gluconate solutions can
vary, we also tested the present embodiment of the filter assembly 10 with calcium gluconate solutions that had been spiked with added Al to give total Al concentrations of 8,000 and 11,200 micrograms/L. The filter assembly 10 removed 94% and 90% of the aluminum, respectively, from these spiked solutions
[0041] The foregoing has been presented for purposes of illustration and description.
It is not intended to be exhaustive or to limit the embodiments to the precise form disclosed. Obvious modifications and variations are possible in light of the above teachings. All such modifications and variations are within the scope of the appended claims when interpreted in accordance with the breadth to which they are fairly, legally and equitably entitled.
Claims
1. A flow-through filter assembly for removing trivalent and tetravalent metal ions from a solution, comprising:
a housing containing a trihydroxamate chelating resin, said housing having an inlet and an outlet;
a first container connector in fluid communication with said inlet;
a second container connector in fluid communication with said outlet; and a flow controller for limiting flow through said housing to a predetermined rate.
2. The filter of claim 1, wherein said predetermined rate is between 0.1 and 10 ml/min.
3. The filter of claim 1 wherein said predetermined rate is less than 2.0 ml/min.
4. The filter of claim 1, wherein said predetermined rate is less than 1.0 ml/min.
5. The filter of claim 1, wherein said predetermined rate is about 1.0 ml/min.
6. The filter of claim 1, wherein said first container connector includes a vented spike and a first set of connector clips.
7. The filter of claim 1, wherein said second container connector includes a non-vented spike and a second set of connector clips.
8. The filter of claim 1, wherein said second vial has a negative interior pressure.
9. The filter of claim 1, wherein said flow controller comprises a flow restrictor tube having a flow passage with a predetermined length L of between about 5 mm and about 20 mm and a predetermined inner diameter of between about 0.0508 mm and about 0.1778 mm.
10. A system for removing a trivalent or tetravalent metal ion from a solution, comprising:
a first container including a solution from which said trivalent or tetravalent metal ion is to be removed;
a second container for receiving a treated solution, said second vial having a negative interior pressure;
a filter assembly for capturing and containing the trivalent or tetravalent metal ion, said filter assembly being connected between said first container and said second container.
11. The system of claim 10, wherein said filter assembly includes a first connector for said first container and a second connector for said second container.
12. The system of claim 11, wherein said first connector is a vented spike and a first clamp.
13. The system of claim 11, wherein said second connector is a non- vented spike and a second clamp.
14. The system of claim 11, wherein said first connector is a vented spike and a first clamp and said second connector is a non-vented spike and a second clamp.
15. The system of claim 10, wherein said filter assembly includes a flow controller comprising a flow restrictor tube having a flow passage with a predetermined length L of between about 5 mm and about 20 mm, a predetermined inner diameter D of between about 0.0508 mm and about 0.1778 mm and said second container has a negative interior pressure of between about 84,659.72 pascals and about 94,818.88 pascals, whereby said flow passage length L, said flow passage diameter D and said second container pressure P function together to provide a rate of flow of solution through said filter assembly of between about 0.1 ml/min and about 10.0 ml/min.
16. A flow-through filter assembly for removing aluminum metal ions from a medical solution including said aluminum metal ions comprising:
a housing including a medical solution inlet;
an aluminum metal ion capturing agent having an Al-binding constant of at least
-10 20 held in said housing;
a treated medical solution outlet positioned on said housing relative to said medical solution inlet to allow for flow of medical solution through said filter assembly without a mechanical pump; and
a flow controller for maintaining a rate of flow of medical solution through said filter assembly that allows capture of aluminum metal ions by said capturing agent.
17. The filter assembly of claim 16, wherein said rate of flow is less than 2.0 ml/min.
18. The filter assembly of claim 16, wherein said rate of flow is between about 0.1 ml/min and about 10.0 ml/min.
19. The filter assembly of claim 16, wherein said resin is a trihydroxamate chelating resin.
20. The filter assembly of claim 16, wherein said aluminum metal ion capturing agent is selected from a group consisting of trihydroxamate chelating resin, desferoxamine chelating resin, tetrahydroxamate chelating resin, hydroxypyridinone chelating resin, aminocarboxylate chelating resin, tricatechol chelating resin, poly-carboxylate chelating resin and mixtures thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361768006P | 2013-02-22 | 2013-02-22 | |
| US61/768,006 | 2013-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014130778A1 true WO2014130778A1 (en) | 2014-08-28 |
Family
ID=51391840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2014/017608 Ceased WO2014130778A1 (en) | 2013-02-22 | 2014-02-21 | A flow-through filter to remove aluminum from medical solutions |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2014130778A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016200559A1 (en) * | 2015-06-09 | 2016-12-15 | Seeo, Inc. | Peo-based graft copolymers with pendant fluorinated groups for use as electrolytes |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5119860A (en) * | 1990-10-15 | 1992-06-09 | Water Factory Systems | Flow restrictor for water purification systems |
| US5538638A (en) * | 1994-06-27 | 1996-07-23 | Hedman; Hilary R. | Method of testing IV admixtures for contaminants |
| US20030100125A1 (en) * | 2001-10-19 | 2003-05-29 | Monogen, Inc. | Flow control metering system and method for controlling filtration of liquid-based specimens |
| US20120061325A1 (en) * | 2008-04-16 | 2012-03-15 | Yokel Robert A | Chelating compounds and immobilized tethered chelators |
-
2014
- 2014-02-21 WO PCT/US2014/017608 patent/WO2014130778A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5119860A (en) * | 1990-10-15 | 1992-06-09 | Water Factory Systems | Flow restrictor for water purification systems |
| US5538638A (en) * | 1994-06-27 | 1996-07-23 | Hedman; Hilary R. | Method of testing IV admixtures for contaminants |
| US20030100125A1 (en) * | 2001-10-19 | 2003-05-29 | Monogen, Inc. | Flow control metering system and method for controlling filtration of liquid-based specimens |
| US20120061325A1 (en) * | 2008-04-16 | 2012-03-15 | Yokel Robert A | Chelating compounds and immobilized tethered chelators |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016200559A1 (en) * | 2015-06-09 | 2016-12-15 | Seeo, Inc. | Peo-based graft copolymers with pendant fluorinated groups for use as electrolytes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9138529B2 (en) | Anticoagulant-free dialysis systems and methods | |
| JP6259108B2 (en) | Cartridge useful for dialysis solution purification | |
| EP1345687B1 (en) | Cartridges useful in cleaning dialysis solutions | |
| US20220401634A1 (en) | Sorbent for a dialysis device and dialysis system | |
| JP5732676B2 (en) | Dialysis composition, hemodialysis system and hemodialyzer | |
| JP7642878B2 (en) | Intradialytic use of sodium thiosulfate | |
| IE80682B1 (en) | Filter for liquor filtration | |
| JPH0567305B2 (en) | ||
| US4309992A (en) | Microbicidal filter | |
| JP2024174935A (en) | Intradialytic use of sodium nitrite | |
| US4300551A (en) | Method for treating schizophrenia | |
| JP2000334037A (en) | Removal of enveloped viruses from blood, plasma or serum | |
| WO2014130778A1 (en) | A flow-through filter to remove aluminum from medical solutions | |
| US9259670B2 (en) | Flow-through filter to remove aluminum from medical solutions | |
| De Francisco et al. | Haemodiafiltration with sorbent-regenerated ultrafiltrate as replacement fluid: a multicenter study. | |
| CN104257604B (en) | Hydroxyethyl starch sodium chloride injection and preparation method thereof | |
| JP2584261B2 (en) | Hemoglobin adsorbent | |
| JP2022516981A (en) | Plasma detoxification methods and systems | |
| BR112019011224B1 (en) | SORBENT FOR A DIALYSIS DEVICE AND A DIALYSIS SYSTEM | |
| HK1059061B (en) | Cartridges useful in cleaning dialysis solutions | |
| JP2006280819A (en) | Bile acid removal method and apparatus, and blood purification agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14753782 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14753782 Country of ref document: EP Kind code of ref document: A1 |